Conferences - Results from #20

Viewing 21-40 of 11869 articles

SUO 2024: Clinical Progression of Prostate Cancer from Active Surveillance is Predicted by Decipher® Genomic Classifier Score on Index Biopsy Independent from Risk Assessment by MRI Characteristics

SUO 2024: CORE-008: A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk NMIBC

SUO 2024: Genitourinary Cancer Care among Geriatric Patients

SUO 2024: Access to Care for Resource Challenged Populations: Tele-Cystoscopy

SUO 2024: The Cretostimogene Grenadenorepvec Expanded Access Program in Patients with NMIBC Unresponsive to BCG

SUO 2024: Multicenter Experience with First-Line Intravesical Gemcitabine-Docetaxel Versus Bacillus Calmette-Guerin for High-Risk NMIBC

SUO 2024: Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting

SUO 2024: AI in Prostate Cancer: Diagnostic Hype and Hope

SUO 2024: Incidence and Pathologic Outcomes of Cystectomy in Patients with BCG-Unresponsive NMIBC with CIS Following Treatment with Nadofaragene Firadenovec

SUO 2024: An Artificial Intelligence Powered Model to Predict Response to Intravesical BCG Versus Gemcitabine-Docetaxel for High Risk NMIBC

SUO 2024: Co-formulated Vibostolimab/pembrolizumab or Co-formulated Favezelimab/pembrolizumab for Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle Invasive Bladder Cancer: Cohort C of Phase II KEYNOTE-057 Trial

SUO 2024: A Phase I Dose-Escalation Study of UGN-301 (Zalifrelimab) as Monotherapy and in Combination with Other Agents in Patients with Recurrent Non-muscle Invasive Bladder Cancer

SUO 2024: ADVANCED-2: Phase 2 Open-Label Study to Evaluate Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer

SUO 2024: Prostate Cancer Screening with Biomarkers and MRI–A European Perspective

SUO 2024: The Impact of BCG Shortage on Disease Recurrence for Patients with Non-Muscle Invasive Bladder Cancer: A SEER Patterns of Care Analysis.

SUO 2024: Voided Urine Cell-Free DNA as a Biomarker for Upper Tract Urothelial Carcinoma

SUO 2024: Measuring and Mitigating Decision Regret in the Management of Genitourinary Cancers: Honing our Shared Decision-Making Skills

SUO 2024: Moonrise-1: Phase 3 Study of TAR-210, an Erdafitinib Intravesical Targeted Releasing System, Versus Intravesical Chemotherapy in Patients with FGFR-Altered Intermediate Risk Non Muscle Invasive Bladder Cancer

SUO 2024: Long-Term Outcomes of Primary Chemoablation of Low-Grade UTUC with UGN-101, a Mitomycin Reverse Thermal Gel

SUO 2024: Initial Results of a Multicenter Phase II trial of Intravesical Gemcitabine plus BCG for Patients with BCG-exposed Non-muscle Invasive Bladder Cancer

1
2
3
4
5
6
7
8
9
10